All Pharma News
Inotrem Reaches Agreement with the FDA for a Phase 3 Trial for Nangibotide

Inotrem Reaches Agreement with the FDA for a Phase 3 Trial for Nangibotide
BUSINESSWIRE
08 Jan 2024
Share Share
Inotrem Receives Funding From the Crohn’s & Colitis Foundation Ventures Program

Inotrem Receives Funding From the Crohn’s & Colitis Foundation Ventures Program
BUSINESSWIRE
06 Nov 2023
Share Share
Inotrem Announces Publication of Two Key Articles on Nangibotide PII Programs

Inotrem Announces Publication of Two Key Articles on Nangibotide PII Programs
BUSINESSWIRE
01 Jun 2023
Share Share
Inotrem Receives Funding From the Crohn’s & Colitis Foundation for IBD

Inotrem Receives Funding From the Crohn’s & Colitis Foundation for IBD
BUSINESSWIRE
09 Jan 2023
Share Share
Inotrem Announces That the PII Study for Treatment of COVID-19 Meets Endpoints

Inotrem Announces That the PII Study for Treatment of COVID-19 Meets Endpoints
BUSINESSWIRE
25 Oct 2022
Share Share
Inotrem posts 2nd data drop of the month, this time for COVID

Inotrem posts 2nd data drop of the month, this time for COVID
Gabrielle Masson FIERCEBIOTECH
25 Oct 2022
Share Share
Inotrem Announces Positive Outcome of its Phase II ASTONISH Trial

Inotrem Announces Positive Outcome of its Phase II ASTONISH Trial
BUSINESSWIRE
13 Oct 2022
Share Share
Inotrem sparks hope with new phase 2b data

Inotrem sparks hope with new phase 2b data
Gabrielle Masson FIERCEBIOTECH
13 Oct 2022
Share Share
Inotrem and the Crohn’s & Colitis Foundation Sign a R&D Collaboration Agreement

Inotrem and the Crohn’s & Colitis Foundation Sign a R&D Collaboration Agreement
BUSINESSWIRE
14 Apr 2022
Share Share
Inotrem Adds a New Strategic Asset to Its Immunotherapy Anti-TREM-1 Pipeline

Inotrem Adds a New Strategic Asset to Its Immunotherapy Anti-TREM-1 Pipeline
BUSINESSWIRE
23 Jun 2021
Share Share